MedTrace Logo

Effect of Bifidobacterium Breve B-3 on Body Fat in Obese Adults

NCT03774381 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-09-11

No results posted yet for this study

Summary

Comparison of a randomized, double-blind, and control-group study for the effect of oral ingestion of Bifidobacterium breve B-3 on body fat reduction in obese adults

Conditions

Interventions

DIETARY_SUPPLEMENT

Bifidobacterium breve B-3

160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.

DIETARY_SUPPLEMENT

Control group

160 mg of placebo is orally administered per day for 12 weeks.

Sponsors & Collaborators

  • Pusan National University Yangsan Hospital

    lead OTHER

Principal Investigators

  • Sang Yeoup Lee, MD · Pusan National University Yangsan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2019-07-31
Completion
2019-08-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03774381 on ClinicalTrials.gov